ATIQCTPC targeting MMP-9: a key step to slowing primary tumor growth and inhibiting metastasis of lewis lung carcinoma in vivo

Yuji Wang, Xinyi Xu, Ce Song, Jianhui Wu, Xi Hu, Haimei Zhu, Xiaoyi Zhang, Yaonan Wang, Lin Gui, Ming Zhao, Shiqi PengOncotarget 2017 · DOI

TL;DR

This paper introduces ATIQCTPC, a novel compound designed to inhibit Matrix Metalloproteinase-9 (MMP-9). ATIQCTPC demonstrates significant efficacy in slowing primary tumor growth and inhibiting metastasis in Lewis lung carcinoma models, while also reducing inflammation. Its potent activity and favorable safety profile suggest it's a promising therapeutic candidate.

What Problem Does This Paper Address?

Cancer metastasis, the spread of cancer cells from the primary tumor to other parts of the body, is a major cause of cancer-related deaths. Matrix Metalloproteinase-9 (MMP-9) is a key enzyme implicated in various stages of cancer progression, including tumor growth, invasion, and metastasis. While many MMP-9 inhibitors have been developed, most have only been evaluated in vitro. There's a critical need for effective in vivo MMP-9 inhibitors that can translate to therapeutic benefits. This paper addresses this gap by designing, synthesizing, and evaluating a novel MMP-9 inhibitor, ATIQCTPC, for its efficacy in slowing tumor growth and preventing metastasis in a living organism.

Methods

The researchers employed a multi-pronged approach:

  • Computational Docking: They used molecular docking (specifically, libdock scores) to predict how well ATIQCTPC binds to the active site of MMP-9, comparing it to other potential inhibitors and a standard ligand. This helped in the rational design of the compound.
  • In Vitro Assays: Standard cell migration and invasion assays using A549 (lung cancer) and Lewis lung carcinoma (LLC) cell lines were performed to assess ATIQCTPC's ability to inhibit cancer cell movement.
  • In Vivo Tumor Models: Lewis lung carcinoma (LLC) cells were implanted into C57BL/6 mice to create primary tumors and study metastasis. The mice were treated with ATIQCTPC, its parent compound ATIQC, or a control (NS - normal saline).
  • Tumor Growth and Metastasis Measurement: Primary tumor weight and volume were measured. The number of lung metastasis nodules was quantified.
  • Inflammation Model: Xylene-induced ear edema was used as a model to evaluate ATIQCTPC's anti-inflammatory properties.
  • Biochemical Assays: Serum levels of MMP-9, TNF-α (Tumor Necrosis Factor-alpha), and IL-8 (Interleukin-8) were measured using ELISA kits to assess the compound's systemic effects.
  • Histological Analysis: Hematoxylin and eosin (H&E) staining was used to examine the histology of heart tissue to assess potential toxicity.
  • Organ Function Tests: Serum levels of ALT (Alanine transaminase), AST (Aspartate transaminase), and Cr (Creatinine) were measured to evaluate liver and kidney function.
  • Free Radical Scavenging Assay: Electron Spin Resonance (ESR) spectroscopy was used to assess ATIQCTPC's ability to scavenge NO• (nitric oxide) free radicals.

Datasets

Not explicitly discussed as "datasets" in the traditional machine learning sense. The study utilizes:

  • Lewis Lung Carcinoma (LLC) cells and A549 cells: These are standard cell lines used for cancer research.
  • C57BL/6 mice and ICR mice: These are common laboratory animal models for cancer and inflammation studies, respectively.
  • MMP-9 protein structure: Used for computational docking.

Key Insights and Ideas

  • Rational Drug Design Pays Off: The computational docking approach successfully guided the design of ATIQCTPC, leading to a compound with predicted high affinity for MMP-9. This highlights the power of integrating computational methods into drug discovery.
  • Dual Action: Tumor Growth and Metastasis Inhibition: ATIQCTPC doesn't just target metastasis; it also significantly slows down the growth of the primary tumor. This dual action is crucial for a more effective cancer therapy.
  • Potent Anti-inflammatory Effects: The compound effectively reduces inflammation, which is often intertwined with cancer progression. This suggests a broader therapeutic potential beyond just MMP-9 inhibition.
  • Superiority over Parent Compound and Aspirin: ATIQCTPC shows significantly higher potency than its parent compound (ATIQC) and even aspirin in certain aspects, indicating an optimized molecular design.
  • Safety Profile: Crucially, at doses significantly higher than its effective therapeutic dose, ATIQCTPC shows no apparent toxicity to the kidney, liver, or heart, suggesting a good safety window.
  • NO• Radical Scavenging: The ability of ATIQCTPC to scavenge NO• free radicals provides a potential mechanistic link between its anti-inflammatory and anti-cancer effects, as NO• is implicated in both processes.

Key Results

  • In Vitro: ATIQCTPC demonstrated dose-dependent inhibition of A549 and LLC cell migration and invasion, with an activity 100-fold greater than its parent compound, ATIQC.
  • In Vivo Metastasis: ATIQCTPC (0.01 µmol/kg) significantly reduced lung metastasis nodules in LLC-bearing mice, showing an activity 100-fold higher than ATIQC (1 µmol/kg).
  • In Vivo Tumor Growth: ATIQCTPC (0.01 µmol/kg) effectively slowed LLC sarcoma growth, with comparable efficacy to ATIQC (1 µmol/kg), indicating a 100-fold increase in potency.
  • Serum and Tumor MMP-9 Levels: Treatment with ATIQCTPC significantly reduced MMP-9 levels in both serum and primary tumors of LLC-bearing mice.
  • Anti-inflammatory Activity: ATIQCTPC inhibited xylene-induced ear edema in a dose-dependent manner. The minimal effective dose (0.01 µmol/kg) was 100-fold more potent than ATIQC and comparable to 110-fold higher dose of aspirin.
  • Inflammatory Markers: ATIQCTPC (0.01 µmol/kg) effectively reduced serum TNF-α and IL-8 levels in inflammatory mice.
  • Safety: At 1 µmol/kg, ATIQCTPC did not cause significant changes in ALT, AST, or Cr levels, nor did it induce observable damage to heart tissue.

Limitations and Future Work

  • Mechanism of Action: While the study demonstrates ATIQCTPC's efficacy and suggests mechanisms (MMP-9 inhibition, NO• scavenging), a more in-depth exploration of the precise molecular pathways involved in its anti-tumor and anti-inflammatory actions could be beneficial.
  • Pharmacokinetics and Pharmacodynamics: Detailed studies on how ATIQCTPC is absorbed, distributed, metabolized, and excreted in vivo, as well as its long-term effects, would be crucial for clinical translation.
  • Broader Cancer Types: The study focused on Lewis lung carcinoma. Investigating ATIQCTPC's efficacy in other cancer types where MMP-9 plays a significant role would expand its potential therapeutic applications.
  • Combination Therapies: Exploring the synergistic effects of ATIQCTPC with existing cancer therapies could lead to more potent treatment strategies.
  • Clinical Trials: The ultimate validation of ATIQCTPC's therapeutic potential would come from well-designed clinical trials in human patients.

Summary updated

Abstract

In this study we docked (6S)-3-acetyl-4-oxo-N-(2-(3,4,5,6-zetrahydroxytetrahydro-2H-pyran-2-carboxamido)ethyl)-4,6,7,12-tetrahydroindolo[2,3-a]quinolizine-6-carbo-xamide (ATIQCTPC) towards the active site of MMP-9, and showed that ATIQCTPC was able to effectively decrease the level of MMP-9 in the serum and the primary tumor of Lewis lung carcinoma (LLC) implanted C57BL/6 mice. As a MMP-9 inhibitor, ATIQCTPC inhibited the metastasis of LLC, and slowed the growth of the primary tumor of LLC implanted C57BL/6 in mice. The activities of ATIQCTPC to inhibit the ear edema and to decrease the serum levels of TNF-α and IL-8 of the mice treated with xylene were explored. The minimal effective dose of ATIQCTPC that can inhibit the primary tumour growth, prevent the metastasis of LLC and reduce the inflammatory response was 0.01 μmol/kg. The minimal effective dose of ATIQCTPC inhibiting tumour growth and metastasis was 100-fold lower than that of (S)-3-acetyl- 4-oxo-4,6,7,12-tetrahydroindolo[2,3-a]quinolizine-6-carboxylic acid (ATIQC, parent compound). The minimal effective dose of ATIQCTPC inhibiting inflammation was 110-fold lower than that of aspirin. These superiorities reflected the rationality of ATIQCTPC design. The safety of the therapy was explained by 1 μmol/kg of ATIQCTPC did not injure the kidney, the liver and the heart of the treated inflammation mice.
BibTeX
@inproceedings{wang2017atiqctpc,
  author = {Yuji Wang and Xinyi Xu and Ce Song and Jianhui Wu and Xi Hu and Haimei Zhu and Xiaoyi Zhang and Yaonan Wang and Lin Gui and Ming Zhao and Shiqi Peng},
  title = {{ATIQCTPC targeting MMP-9: a key step to slowing primary tumor growth and inhibiting metastasis of lewis lung carcinoma <i>in vivo</i>}},
  booktitle = {Oncotarget},
  year = {2017},
  doi = {10.18632/oncotarget.19172},
}
Figure